Episode Details
Back to Episodes320: Jim Wilson's next venture, a surprise startup shutdown, & Lilly's Zepbound strategy
Published 2 years, 1 month ago
Description
STAT biotech reporter Jonathan Wosen joins us to discuss gene therapy pioneer Jim Wilson's exit from his decades-long tenure at the University of Pennsylvania. We also discuss the latest news in the life sciences, including the surprising collapse of a gene editing company, Eli Lilly's pitch to consumers, and more.